Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review
International Journal of Microbiology · 2026-01 · 2026 (1)
DOI: 10.1155/ijm/6935819 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Microbiology, online erschienen am 28.03.2026. Verfasst von Nura Bello und 7 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northern Border University.
Abstract (Originalsprache)
Background
C–X–C motif chemokine ligand 13 (CXCL13) is a critical chemokine for lymphoid organization and immune cell migration during hepatitis B virus (HBV) infection. This systematic review assessed the function of CXCL13 in HBV immunoregulation, pathogenesis, genetic susceptibility, and treatment outcome.
Methods
We systematically searched five databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify studies reporting on CXCL13 expression, genetic variants, and clinical outcomes in the context of HBV infection. Thirteen qualified studies were identified and assessed using standard quality appraisal instruments.
Results
Data consistently supported the role of CXCL13 in recruiting CXCR5 T and B cells, conditioning germinal center–like reaction(s) as well as antiviral immune responses. Elevated serum CXCL13 levels correlated with better virological response, higher HBsAg clearance, and more favorable response to PegIFNα and nucleos(t)ide analogs. On the other hand, downregulation of CXCL13 was associated with immune tolerance, resistance failure, and disease persistence. Genetically, these polymorphic sites, such as rs355687 and rs76084459, have been associated with vaccine response, the possibility of transplacental transmission, and outcomes of antiviral therapy.
Conclusion
CXCL13 is a key immunomodulatory factor in HBV infection and represents an excellent candidate predictive biomarker for treatment response and disease course. Prospective multicenter studies and laboratory research are needed to confirm its usefulness in clinical trials and to investigate therapeutic strategies targeting CXCL13.
Förderung
- Northern Border University
Zitieren
APA
Bello, N., Hudu, S. A., Tahir, A., Abubakar, N., Shinkafi, S. H., Adamu, A. A., Imam, M. U., & Jimoh, A. O. (2026). Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review. International Journal of Microbiology, 2026(1). https://doi.org/10.1155/ijm/6935819
Vancouver
Bello N, Hudu SA, Tahir A, Abubakar N, Shinkafi SH, Adamu AA, et al. Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review. International Journal of Microbiology. 2026;2026(1). doi:10.1155/ijm/6935819
BibTeX
@article{Bello2026,
author = {Bello, Nura and Hudu, Shuaibu Abdullahi and Tahir, Albashir and Abubakar, Nura and Shinkafi, Sa’adatu Haruna and Adamu, Adamu Ahmed and Imam, Mustapha Umar and Jimoh, Abdulgafar Olayiwola},
title = {Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review},
journal = {International Journal of Microbiology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijm/6935819}
}
EUVIMED